Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Arcadia Biosciences (RKDA) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Arcadia Biosciences (RKDA) over the last 12 years, with Q3 2025 value amounting to 88.48%.

  • Arcadia Biosciences' EBIT Margin rose 260300.0% to 88.48% in Q3 2025 from the same period last year, while for Sep 2025 it was 65.76%, marking a year-over-year decrease of 101800.0%. This contributed to the annual value of 72.31% for FY2024, which is 646900.0% up from last year.
  • According to the latest figures from Q3 2025, Arcadia Biosciences' EBIT Margin is 88.48%, which was up 260300.0% from 34.43% recorded in Q2 2025.
  • In the past 5 years, Arcadia Biosciences' EBIT Margin ranged from a high of 151.61% in Q2 2024 and a low of 643.24% during Q1 2021
  • Moreover, its 5-year median value for EBIT Margin was 143.57% (2022), whereas its average is 177.42%.
  • Examining YoY changes over the last 5 years, Arcadia Biosciences' EBIT Margin showed a top increase of 29777900bps in 2021 and a maximum decrease of -4503300bps in 2021.
  • Quarter analysis of 5 years shows Arcadia Biosciences' EBIT Margin stood at 321.02% in 2021, then skyrocketed by 125bps to 80.14% in 2022, then crashed by -292bps to 153.54% in 2023, then decreased by -22bps to 187.42% in 2024, then surged by 53bps to 88.48% in 2025.
  • Its last three reported values are 88.48% in Q3 2025, 34.43% for Q2 2025, and 44.17% during Q1 2025.